» Articles » PMID: 39595931

Enzyme (α-Glucosidase, α-Amylase, PTP1B & VEGFR-2) Inhibition and Cytotoxicity of Fluorinated Benzenesulfonic Ester Derivatives of the 5-Substituted 2-Hydroxy-3-nitroacetophenones

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Nov 27
PMID 39595931
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of small multi-target drugs containing a fluorinated aromatic moiety among approved drugs in the market is due to the unique properties of this halogen atom. With the aim to develop potent antidiabetic agents, a series of phenylsulfonic esters based on the conjugation of the 5-substituted 2-hydroxy-3-nitroacetophenones - with phenylsulfonyl chloride derivatives substituted with a fluorine atom or fluorine-containing (-CF or -OCF) group were prepared. Their structures were characterized using a combination of spectroscopic techniques complemented with a single-crystal X-ray diffraction (XRD) analysis on a representative example. The compounds were, in turn, assayed for inhibitory effect against α-glucosidase, α-amylase, protein tyrosine phosphatase 1 B (PTP1B) and the vascular endothelial growth factor receptor-2 (VEGFR-2) all of which are associated with the pathogenesis and progression of type 2 diabetes mellitus (T2DM). The antigrowth effect of selected compounds was evaluated on the human breast (MCF-7) and lung (A549) cancer cell lines. The compounds were also evaluated for cytotoxicity against the African Green Monkey kidney (Vero) cell line. The results of an in vitro enzymatic study were augmented by molecular docking (in silico) analysis. Their ADME (absorption, distribution, metabolism and excretion) properties have been evaluated on the most active compounds against α-glucosidase and/or α-amylase to predict their drug likeness.

References
1.
Olender D, Zwawiak J, Zaprutko L . Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines. Pharmaceuticals (Basel). 2018; 11(2). PMC: 6027522. DOI: 10.3390/ph11020054. View

2.
Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T . Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019; 58(9):1131-1147. PMC: 6719436. DOI: 10.1007/s40262-019-00766-0. View

3.
Sun D, Nakao S, Xie F, Zandi S, Bagheri A, Kanavi M . Molecular imaging reveals elevated VEGFR-2 expression in retinal capillaries in diabetes: a novel biomarker for early diagnosis. FASEB J. 2014; 28(9):3942-51. PMC: 4139900. DOI: 10.1096/fj.14-251934. View

4.
Gong L, Feng D, Wang T, Ren Y, Liu Y, Wang J . Inhibitors of α-amylase and α-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. Food Sci Nutr. 2020; 8(12):6320-6337. PMC: 7723208. DOI: 10.1002/fsn3.1987. View

5.
Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View